Search Result

Results for "

lipogenesis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (2) AMPK (2) Apoptosis (1) ATP Citrate Lyase (1) Drug Derivative (1) Endogenous Metabolite (4) Fatty Acid Synthase (FASN) (4) Herbicide (2) Insulin Receptor (1) Ketohexokinase (1) LXR (2) mTOR (2) PPAR (3) Reactive Oxygen Species (1) Sirtuin (1) Stearoyl-CoA Desaturase (SCD) (2) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (3) Metabolic Disease (20)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139576B

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-W058849

MT 63-78	AMPK mTOR Apoptosis	Cancer
MT 63-78 is a specific and potent direct AMPK activator with an EC₅₀ of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects .

HY-12756A

E6446 dihydrochloride 1 Publications Verification	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-12756

E6446 1 Publications Verification	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-N0458

Pedunculoside 1 Publications Verification	Fatty Acid Synthase (FASN)	Metabolic Disease
Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .

HY-W564704

(p-Hydroxybenzyl)malonic acid	Drug Derivative	Metabolic Disease
(p-Hydroxybenzyl)malonic acid is a hydroxyphenyl derivative capable of inhibiting insulin-induced lipogenesis in rat adipocytes with an IC₅₀ value of 3.8 μM .

HY-139576

Larsucosterol DUR-928	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576A

Larsucosterol sodium DUR-928 sodium	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-169159

SIRT6 activator 2	Sirtuin	Metabolic Disease
SIRT6 activator 2 (compound 31) is a sirtuin 6 activator with anti-lipid accumulation properties. SIRT6 activator 2 significantly downregulates LXR, SREBP-1c, and their target genes associated with lipogenesis, and can be used for research related to lipid metabolism-related diseases .

HY-119006

L-640,033	Adrenergic Receptor	Endocrinology
L-640,033 is a potent agonist of β-adrenergic. L-640,033 play an important role in lipid metabolism, and growth .

HY-136374

Haloxyfop-P-methyl	Herbicide	Others
Haloxyfop-P-methyl is an aryloxyphenoxypropionate herbicide. Haloxyfop-P-methyl can be absorbed by roots or foliage and hampers lipogenesis and increases oxidative stress in target plants .

HY-D1163

Chromium(III) acetate 1 Publications Verification Chromium acetate; Chromic acetate; Chromium triacetate	AMPK	Metabolic Disease
Chromium(III) acetate (Chromic acetate) is an AMPK inhibitor that promotes lipogenesis by inhibiting AMPK phosphorylation. Chromium(III) acetate has low toxicity in mammals, with an LD₅₀ of 2365 mg/kg in rats .

HY-137996

Dehydrovomifoliol	Akt mTOR	Metabolic Disease
Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

HY-N0458R

Pedunculoside (Standard)	Fatty Acid Synthase (FASN)	Metabolic Disease
Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

HY-119248

KRP-297 MK-0767	PPAR	Metabolic Disease
KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.

HY-16007

(-)-Hydroxycitric acid Garcinia acid	ATP Citrate Lyase	Metabolic Disease
(-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive and orally active inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss .

HY-136374R

Haloxyfop-P-methyl (Standard)	Herbicide	Others
Haloxyfop-P-methyl (Standard) is the analytical standard of Haloxyfop-P-methyl. This product is intended for research and analytical applications. Haloxyfop-P-methyl is an aryloxyphenoxypropionate herbicide. Haloxyfop-P-methyl can be absorbed by roots or foliage and hampers lipogenesis and increases oxidative stress in target plants .

HY-128973

Pyropheophorbide-a	Reactive Oxygen Species	Cancer
Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells .

HY-149987

LY3522348 KHK-IN-3	Ketohexokinase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation .

HY-149540

CTL-06	Fatty Acid Synthase (FASN)	Cancer
CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC₅₀: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-164997

15-keto Prostaglandin F1α 15-keto PGF1α	Endogenous Metabolite	Metabolic Disease
15-keto Prostaglandin F1α (15-keto PGF1α) is a prostaglandin F1α metabolite. 15-keto Prostaglandin F1α (15-keto PGF1α) is an effective substrate for PGR-2. 15-keto Prostaglandin F1α (15-keto PGF1α) can be used to study physiological processes such as prostaglandin metabolism and lipogenesis .

HY-N0723

Neomangiferin	Others	Metabolic Disease
Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .

HY-N0723R

Neomangiferin (Standard)	Others	Metabolic Disease
Neomangiferin (Standard) is the analytical standard of Neomangiferin. This product is intended for research and analytical applications. Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .

HY-149541

CTL-12	Fatty Acid Synthase (FASN)	Cancer
CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC₅₀: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-168049

ZLY06	PPAR Akt	Metabolic Disease
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC₅₀=341 nM; PPAR γ: EC₅₀=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .

HY-146288

LXR agonist 2	LXR	Metabolic Disease
LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism .

HY-108022A

Azemiglitazone potassium MSDC-0602K	Insulin Receptor PPAR	Metabolic Disease
Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC₅₀ of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .

Cat. No.	Product Name

HY-L182

Fatty Acids Compound Library	293 compounds
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases. MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Fatty Acids Compound Library

293 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	LXR Endogenous Metabolite
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

Pedunculoside 1 Publications Verification	Aquifoliaceae Triterpenes Structural Classification Classification of Application Fields Terpenoids Ilex rotunda Thunb. Source classification Metabolic Disease Plants Disease Research Fields	Fatty Acid Synthase (FASN)
Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .

(-)-Hydroxycitric acid Garcinia acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Guttiferae Metabolic Disease Plants Garcinia cambogia Disease Research Fields	ATP Citrate Lyase
(-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive and orally active inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss .

Neomangiferin	Structural Classification Liliaceae Xanthones Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Anemarrhena asphodeloides Bunge Plants Disease Research Fields	Others
Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .

Larsucosterol DUR-928	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

Larsucosterol sodium DUR-928 sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

Dehydrovomifoliol	Artemisia frigida Willd. Structural Classification Terpenoids Sesquiterpenes Source classification Plants Compositae	Akt mTOR
Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

Pedunculoside (Standard)	Aquifoliaceae Triterpenes Structural Classification Terpenoids Ilex rotunda Thunb. Source classification Plants	Fatty Acid Synthase (FASN)
Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

Neomangiferin (Standard)	Structural Classification Liliaceae Xanthones Source classification Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants	Others
Neomangiferin (Standard) is the analytical standard of Neomangiferin. This product is intended for research and analytical applications. Neomangiferin is a natural C-glucosyl xanthone isolated from m the dried rhizome of Anemarrhena asphodeloides. Neomangiferin has significant therapeutic effects on high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) in rats .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks